Glossary
Biologics
These drugs aim at one target instead of damping everything down. That's the whole idea behind them. It explains both what they do well and what they cost you in the process.
What the research found.
One review pooled 21 trials and 8361 people with early rheumatoid arthritis, where adalimumab with methotrexate had the strongest effect on remission, at an odds ratio of 2.90 with the true value from 1.94 to 4.33. Tocilizumab with methotrexate led on the strictest response measure, at 4.41, from 2.29 to 8.49. Those are two different measures rather than one ranking.
That review found only one safety signal in the whole network. Tocilizumab with methotrexate showed more side effects, at an odds ratio of 5.11, with the true value from 2.03 to 12.86. No safety risk was found for any of the other drugs studied.
One trial started 799 people who had never had methotrexate, and at a year 62 percent on adalimumab with methotrexate hit the response target, against 46 percent on methotrexate alone and 41 percent on adalimumab alone. Both comparisons came in at P under 0.001. So the pair beat either drug by itself.
One study tracked 7089 Australians in ordinary practice, where people stayed on upadacitinib a median of 26.6 months against 13.3 months on tumor necrosis factor blockers. The true values sit from 24.9 to 30.8 and from 11.5 to 14.5, at a P value under 0.001. That study watched what happened rather than assigning anybody.
What a biologic is
A biologic is a drug grown in living cells rather than mixed from chemicals, and each one blocks a single signal that the immune system uses to keep inflammation going. That's why they're named for what they block rather than for what they treat. A tumor necrosis factor blocker blocks tumor necrosis factor, and an interleukin 6 blocker blocks interleukin 6.
One consequence of naming a drug by its target is that a drug can turn up in several different diseases. Most of them are given by injection under the skin, or by a drip into a vein, and that isn't for effect or ceremony. A protein that size wouldn't survive being swallowed.
How they differ from the tablets
The older tablets damp the immune system down broadly, and methotrexate is the one most people meet first. A biologic aims at one part of it and leaves the rest alone, which is the argument for them. It's also the reason their risks aren't one risk across the whole class.
Broad damping leaves a broad weakness, while blocking one signal well leaves a specific hole, and which hole depends on which drug. So safety can't be discussed for the group as a whole, however convenient that would be. The evidence here treats them as a group where the trials did, and splits them where the trials did.
What the trials show
One review pooled 21 trials and 8361 people with early rheumatoid arthritis, where several biologics beat methotrexate alone. Two came out ahead of the rest, on two different measures. Adalimumab with methotrexate had the strongest effect on remission, at an odds ratio of 2.90 with the true value somewhere from 1.94 to 4.33.
Tocilizumab with methotrexate led on the strictest response measure, at an odds ratio of 4.41, from 2.29 to 8.49. That review found one safety signal and only one. Tocilizumab with methotrexate showed more side effects, at an odds ratio of 5.11 from 2.03 to 12.86, with nothing showing for the other drugs studied. The authors end by saying the best strategy stays unsettled, because few trials qualified.
An older trial makes the combination point cleanly. It started 799 people who had never taken methotrexate on one of three routes. At a year, 62 percent on adalimumab with methotrexate hit the response target, against 46 percent on methotrexate alone and 41 percent on adalimumab alone, with both comparisons coming in at P under 0.001. Side effects looked alike in all three arms.
The trial that argues the other way
One trial is worth setting against all of that, and it's the reason this page doesn't read as a straightforward endorsement. It took 353 people whose methotrexate alone wasn't enough, and gave each of them either three older tablets together or methotrexate plus a biologic. Disease activity came out level in both arms and stayed stable across the whole trial.
What differed was how long people stayed on their treatment. At a year, 78 percent were still on the three tablets against 63 percent on the biologic route, and more people switched away from the biologic route than toward it, at P equals 0.005. The authors draw the obvious conclusion from that pair of findings.
Given similar outcomes and a large difference in cost, they argue that conventional combinations have a case as the first move after methotrexate fails. That doesn't make biologics wrong. It makes them one option among several rather than the automatic next step after a tablet stops working.
Staying on the drug
How long people stay on a drug is measured separately from how well it works, and the two don't always agree. It's worth knowing both figures before a drug gets chosen. One study tracked 7089 people in ordinary Australian practice.
The median time on upadacitinib was 26.6 months, from 24.9 to 30.8, against 13.3 months on tumor necrosis factor blockers, from 11.5 to 14.5, at a P under 0.001. Against other drugs in its own group it was 28.8 months against 17.2. Read that with care, because nobody was assigned to anything and a newer drug reaches patients and prescribers already inclined to stick with it.
No statistical matching fixes what was never written down, and the study's own record here notes it. One finding from that study comes out cleaner than the rest. Taking upadacitinib alone gave much the same staying power as taking it with a tablet, at 27.8 months against 30.4 months, at a P value of 0.84.
Which tablet goes with it
Most people take a tablet alongside their biologic, and which tablet turns out to be a real question rather than a formality, because the trials show it changes the result. One review asked that question across several biologic families. The answers differ by which biologic somebody is on.
Alongside rituximab, a good response was more common on leflunomide than on methotrexate, at a risk ratio of 1.38 from 1.13 to 1.68, at P equals 0.001, across 2078 people. Side effect rates were alike between the two. Alongside a tumor necrosis factor blocker it went the other way, where a tablet other than methotrexate gave a worse response at six months, at a risk ratio of 0.93 from 0.87 to 1.0, and people stayed on it less too.
Alongside abatacept the two tablets were alike. For tocilizumab and the newer targeted tablets, too few trials existed to pool at all. So the pairing is worth asking about rather than assuming.
Dropping the tablet
Some people end up on a biologic alone. One registry watched people already in remission or low disease activity, all of whom were on etanercept plus a tablet, and some of whom then dropped the tablet while others kept both. At two years, 75 percent on etanercept alone were still in remission or low activity against 86 percent on the pair, at an adjusted P value of 0.057.
That doesn't clear the usual line, so this isn't a demonstration that the two approaches are equal. One detail complicates it further, and it runs in the direction that flatters the single drug. Far more of the single-drug group left the count for a treatment change, at 37 percent against 5 percent, mostly because a tablet had been put back.
Those people are removed from the comparison rather than counted as failures. So the 75 percent describes the people who stayed on one drug rather than everybody who tried it. That's a distinction worth holding when somebody quotes the figure at you.
Beyond the joints
These drugs get measured on more than joints, and sleep is one of the things they get measured on. The evidence there points one way. A trial gave adalimumab to people with active ankylosing spondylitis, and by week 12 every sleep measure on the scale used had improved, all at P under 0.001.
The effect sizes were moderate, and sleep quantity rose from 6.2 to 6.6 hours a night, which the authors describe as a small effect. Two reviews report the same direction as that trial. One in psoriatic arthritis found tumor necrosis factor blockers among the treatments linked to better sleep.
One in axial spondyloarthritis went further than that. It concluded this drug group does reduce poor sleep, and it said exercise has produced good results too, while noting that research into non-drug approaches is thin. That last point is worth remembering, because thin research is not the same finding as a treatment that doesn't work.
Common misconceptions.
Myth. A biologic is just a stronger kind of tablet.
Reality. It works a different way entirely. A tablet like methotrexate damps the whole immune system down, while a biologic blocks one signal and leaves the rest alone, which is why each one is named for what it blocks. It also explains the main risk, because damping everything leaves a broad weak spot while blocking one signal leaves a small and precise one.
Myth. If the tablets aren't working, a biologic is the next step.
Reality. That's one option, and the trials don't make it the only one. One trial took people whose methotrexate wasn't enough and gave them either three older tablets together or methotrexate plus a biologic, where disease activity came out level and people stayed on the three tablets longer, at 78 percent against 63 percent at a year. The authors also point at the cost difference.
Myth. They all work about alike.
Reality. The rankings say otherwise, with one caution attached. One review pooled 21 trials and 8361 people, where adalimumab with methotrexate came first for remission, at an odds ratio of 2.90 from 1.94 to 4.33. Tocilizumab with methotrexate led on the strictest measure instead, at 4.41 from 2.29 to 8.49. Those same authors say the best plan stays unsettled, because too few trials qualified.
Myth. I have to take methotrexate alongside it.
Reality. Often yes, and not always. One registry watched people already in remission on etanercept plus a tablet, some of whom then dropped the tablet, and at two years 75 percent of those were still in remission or low activity against 86 percent on the pair. The adjusted P value was 0.057, which doesn't show the two are equal and doesn't show the tablet is essential either.
Myth. Any tablet will do as the partner drug.
Reality. It depends which biologic you're on. One review found that alongside rituximab, leflunomide beat methotrexate for a good response, at a risk ratio of 1.38 from 1.13 to 1.68. Alongside abatacept the two were alike, and alongside a tumor necrosis factor blocker methotrexate did better, at a risk ratio of 0.93 from 0.87 to 1.0. So the pairing is a real decision.
Related terms.
- DMARDs, the older tablets these are compared against.
- Biologics compared with DMARDs, for the head-to-head evidence in one place.
- Rheumatoid arthritis, where most of this evidence comes from.
- Ankylosing spondylitis, where the sleep evidence comes from.
Questions patients ask.
What is a biologic?
A drug grown in living cells rather than mixed in a lab, where each one blocks a single signal the immune system uses, which is why they're named for their target rather than their disease. Most are given by injection under the skin, or by a drip, and that isn't for effect. A protein that size wouldn't survive your stomach.
How is that different from methotrexate?
Scale, mostly. Methotrexate damps the whole immune system down, while a biologic blocks one signal and leaves the rest, and that aim is both the selling point and the catch. Damping everything leaves a broad weak spot, while blocking one signal leaves a small and precise one, so infection risks differ by drug rather than being one risk across the class.
Are they better than the tablets?
On some measures and not on all of them. One review pooled 21 trials and 8361 people, where several biologics beat methotrexate alone on remission, while another trial set three older tablets against methotrexate plus a biologic and found disease control level, with people staying on the tablets longer. So the answer depends on which question you ask.
Do I still take my tablets?
Usually, and which tablet is a real decision rather than a detail. One review looked at the pairings, where leflunomide beat methotrexate alongside rituximab, at a risk ratio of 1.38 from 1.13 to 1.68. Alongside abatacept the two were alike, and alongside a tumor necrosis factor blocker methotrexate did better, so it's worth asking why yours was chosen.
Can I take one on its own?
Some people do. One study followed 84 people taking tocilizumab alone, where it worked and was tolerated about alike either way, whether or not they had taken a biologic before. A registry followed people who dropped their tablet, where two years on 75 percent were still in remission or low activity against 86 percent among those who kept both, at an adjusted P of 0.057.
How long do people stay on them?
It varies a great deal by drug. One study tracked 7089 Australians in ordinary practice, where the median time on upadacitinib was 26.6 months, from 24.9 to 30.8, against 13.3 months on tumor necrosis factor blockers, from 11.5 to 14.5, at a P under 0.001. That study watched what happened rather than assigning anybody to anything.
What about side effects?
They differ by drug, which is the point of the class. One review of 21 trials found only one signal, where tocilizumab with methotrexate had more side effects, at an odds ratio of 5.11 from 2.03 to 12.86, and no safety risk showed for the others. A separate review of one newer drug group was started because of repeated safety warnings, so that question is live.
Do they help anything besides joints?
Some evidence says yes for sleep. One trial gave adalimumab to people with active ankylosing spondylitis, where every sleep measure improved by week 12, all at P under 0.001, and sleep went from 6.2 to 6.6 hours a night, which the authors call a small effect. Two reviews report the same direction across this drug group.
References.
- Xu H; Li C; Ding R et al. Efficacy and safety of non-conventional synthetic disease-modifying antirheumatic drugs in early active rheumatoid arthritis: a network meta-analysis. BMC Rheumatol. 2025;10:5. 10.1186/s41927-025-00603-xSystematic review and network meta-analysis of randomised controlled trials to February 2025
- Breedveld FC; Weisman MH; Kavanaugh AF et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26-37. 10.1002/art.21519PREMIER: two-year
- Youssef P; Ciciriello S; Tahir T et al. Real-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis. Rheumatol Ther. 2025;12:173-202. 10.1007/s40744-024-00736-4Retrospective non-interventional study of electronic medical records from the Australian OPAL dataset
- Peper SM; Lew R; Mikuls T et al. Rheumatoid Arthritis Treatment After Methotrexate: The Durability of Triple Therapy Versus Etanercept. Arthritis Care Res (Hoboken). 2017;69:1467-1472. 10.1002/acr.23255Open-label extension of a 48-week double-blinded noninferiority randomised trial
- Pappas DA; Shan Y; Lesperance T et al. Maintenance of Sustained Low Disease Activity or Remission in Patients With Rheumatoid Arthritis Treated With Etanercept Monotherapy: Results from the Corrona Registry. ACR Open Rheumatol. 2020;2:588-594. 10.1002/acr2.11168Analysis of the Corrona rheumatoid arthritis registry
- Decarriere G; Barnetche T; Combe B et al. Most Appropriate Conventional Disease-Modifying Antirheumatic Drug to Combine With Different Advanced Therapies in Rheumatoid Arthritis: A Systematic Literature Review With Meta-Analysis. Arthritis Care Res (Hoboken). 2021;73:873-884. 10.1002/acr.24195Systematic literature review with meta-analysis comparing methotrexate against other conventional synthetic disease-modifying drugs when combined with advanced therapies in rheumatoid arthritis
- Marsal Barril S; Martin-Martinez MA; Blanco-Garcia FJ et al. Effectiveness and safety of tocilizumab in monotherapy in biologic-naïve and non-naïve patients with rheumatoid arthritis in a real-world setting. Reumatol Clin (Engl Ed). 2022;18:567-573. 10.1016/j.reumae.2021.12.004Prospective multicenter non-controlled study over 32 weeks
- RUDWALEIT M; GOOCH K; MICHEL B et al. Adalimumab Improves Sleep and Sleep Quality in Patients with Active Ankylosing Spondylitis. The Journal of Rheumatology. 2010;38:79-86. 10.3899/jrheum.100213OPEN-LABEL
- O'Neill SM; Leahy J; Harte M et al. The efficacy and safety of Janus kinase inhibitors in adults with rheumatoid arthritis: a systematic review and cumulative meta-analysis. Semin Arthritis Rheum. 2025;75:152885. 10.1016/j.semarthrit.2025.152885Systematic review and cumulative meta-analysis of randomised controlled trials in adults with rheumatoid arthritis treated with a JAK inhibitor against placebo or active treatment
- Choy E; Freemantle N; Proudfoot C et al. Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses. RMD Open. 2019;5:e000798. 10.1136/rmdopen-2018-000798Systematic literature review and network meta-analyses of 24-week efficacy and safety outcomes
- van Vollenhoven R; Strand V; Takeuchi T et al. Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial. Arthritis Res Ther. 2024;26:143. 10.1186/s13075-024-03358-xLong-term extension of the SELECT-EARLY phase 3 randomised controlled trial
This page gathers the published research on this subject into one place. The studies behind it were published between 1989 and 2026, and every figure links to the paper it came from. Those studies were peer reviewed. This summary of them was not. Dr. Sarah Luebker is reviewing these pages one at a time and has not reached this one yet, so it carries no medical review date and nothing here is her opinion or her advice to you. Each page gets updated as she reaches it. It is here in the meantime because the science is worth having in one organized place that is easy to find and easy to read. Talk to your own clinician before acting on any of it.